Loading clinical trials...
Loading clinical trials...
A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered With the Oxulumis® Ophthalmic Administration Device in Subjects With Diabetic Macular Edema
Conditions
Interventions
Triamcinolone Acetonide
Semi-automated Suprachoroidal Microcatheter
Locations
6
United States
California Retina Consultants
Bakersfield, California, United States
Retina Consultants of Minnesota
Minneapolis, Minnesota, United States
Austin Retina Associates
Austin, Texas, United States
Retina Consultants of Texas - The Woodlands
Houston, Texas, United States
Retina Consultants of Texas - Bellaire
Houston, Texas, United States
Retina Consultants of Texas - San Antonio
San Antonio, Texas, United States
Start Date
August 31, 2022
Primary Completion Date
November 30, 2023
Completion Date
November 30, 2023
Last Updated
November 20, 2024
NCT07449936
NCT07449923
NCT07228559
NCT05802329
NCT06781255
NCT06701721
Lead Sponsor
Oxular Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions